DagenaisGRLeongDPRangarajanS, et al.Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. Epub ahead of print 3 September 2019. DOI: 10.1016/S0140-6736(19)32007-0.
2.
YusufSJosephPRangarajanS, et al.Modifiable risk factors, cardiovascular disease, and mortality in 155722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. Epub ahead of print 3 September 2019. DOI: 10.1016/S0140-6736(19)32008-2.
3.
Knuuti J, Wijns W, Saraste A, wt al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. Epub ahead of print 31 August 2019. DOI: 10.1093/eurheartj/ehz425.
4.
NeumannFJSousa-UvaMAhlssonA, et al.2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J2019; 40: 87–165.
5.
EikelboomJWConnollySJBoschJ, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017; 377: 1319–1330.
6.
BonacaMPBhattDLCohenM, et al.Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med2015; 372: 1791–1800.
7.
MauriLKereiakesDJYehRW, et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med2014; 371: 2155–2166.
8.
HochholzerWWiviottSDAntmanEM, et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011; 123: 2681–2689.
9.
Vanassche T, Verhamme P, Anand SS, et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: an analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol 2020; 27: 296–307.
